Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias.
A prospective randomized study of androgen therapy in aplastic anaemia (AA) was performed: 2 androgens (fluoxymesterone and norethandrolone) at high (1 mg/kg/d) and low (0.2 mg/kg/d) dose were studied on 110 patients; and 4 androgens given at high doses were objectively compared in 125 other cases. When patients are matched for AA severity there is an obvious efficiency of the high-dose androgens in the survival of the less severe cases of aplastic anaemia and in their haematological improvement. The data further show that, among the 4 androgens tested, fluoxymesterone is the most efficient and stanozolol the least. We conclude that androgen therapy is truly efficient in moderately severe aplastic anaemia and that fluoxymesterone (1 mg/kg/d) for 18 months should be chosen as reference drug to any new androgen therapy assay.
D000328:Adult; D000368:Aged; D000728:Androgens / Q000627:therapeutic use*; D000741:Anemia, Aplastic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009639:Norethandrolone / Q000627:therapeutic use; D011446:Prospective Studies; D011897:Random Allocation; D013197:Stanozolol / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000031:analogs & derivatives / Q000627:therapeutic use
D000728:Androgens; D013739:Testosterone; D013197:Stanozolol; D005474:Fluoxymesterone; C010792:testosterone undecanoate; D009639:Norethandrolone